Mesothelioma Treatment Options –
A patient newly diagnosed with Mesothelioma cancer is likely to be told their life expectancy is between 8 – 12 months . While this outlook is very grim new advances in modern Mesothelioma cancer treatment are being researched.
In January 2007, the Food and Drug Administration approved the MESOMARK assay to help monitor response to treatment in epithelial and bi-phasic malignant mesothelioma patients. Doctors using this test may be able to better monitor a patient’s progress.
Mesothelioma Treatments - What are your Options?
The 3 most common treatments are:
Surgery - Removing the cancer
Chemotherapy - Uses drugs to fight off the cancer
Radiation Therapy - Uses high dose x-rays to kill the cancer cells
Often 1 or more of these treatment options are used together. If you have been diagnosed with Mesothelioma the sooner you start treatment the better your chances are. Talk to your doctor as soon as possible to begin a treatment plan .
For more detailed information on each of these mesothelioma treatment options please visit: Mesothelioma Web
The course of your treatment will depend on:
Location of the cancer
Stage of the cancer
Your age
Overall health
Mesothelioma Drug Studies
Results from recent studies confirm that Alimta®, Eli Lilly’s FDA-approved drug for mesothelioma, has clinical efficacy for the treatment of malignant pleural mesothelioma. Alimta Therapy is considered the chemotherapy standard of care for treatment of mesothelioma.
ALIMTA® in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.
Read more about ALIMTA® at Alimta.com
Mesothelioma Current Open Clinical trials:
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
Recruitment: Recruiting
Conditions: Mesothelioma
Interventions: Drug: Cisplatin|Drug: Imatinib Mesylate|Drug: Pemetrexed
More Information: http://ClinicalTrials.gov/show/NCT00402766
Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery
Recruitment: Recruiting
Conditions: Malignant Mesothelioma
Interventions: Drug: SS1(dsFv)-PE38 immunotoxin|Drug: cisplatin|Drug: pemetrexed disodium|Procedure: immunoenzyme technique|Procedure: immunohistochemistry staining method|Procedure: pharmacological study|Procedure: quality-of-life assessment
More Information: http://ClinicalTrials.gov/show/NCT00575770
Dasatinib in Resectable Malignant Pleural Mesothelioma
Recruitment: Recruiting
Conditions: Malignant Pleural Mesothelioma
Interventions: Drug: Dasatinib
More Information: http://ClinicalTrials.gov/show/NCT00652574
Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers
Recruitment: Recruiting
Conditions: Lung Cancer|Mesothelioma
Interventions:
More Information: http://ClinicalTrials.gov/show/NCT00188890
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Recruitment: Recruiting
Conditions: Malignant Mesothelioma
Interventions: Drug: dasatinib|Procedure: immunoenzyme technique|Procedure: immunohistochemistry staining method|Procedure: laboratory biomarker analysis
More information: http://ClinicalTrials.gov/show/NCT00509041
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Recruitment: Recruiting
Conditions: Malignant Mesothelioma
Interventions: Drug: pazopanib hydrochloride|Procedure: laboratory biomarker analysis
More information: http://ClinicalTrials.gov/show/NCT00459862
Tomotherapy Treatment for Mesothelioma
Recruitment: Recruiting
Conditions: Mesothelioma
Interventions: Procedure: Tomotherapy
More Information: http://ClinicalTrials.gov/show/NCT00469196
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
Recruitment: Recruiting
Conditions: Malignant Mesothelioma
Interventions: Drug: bortezomib|Procedure: quality-of-life assessment
more Information: http://ClinicalTrials.gov/show/NCT00513877
AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Recruitment: Recruiting
Conditions: Malignant Mesothelioma
Interventions: Drug: cediranib|Procedure: laboratory biomarker analysis
More Information: http://ClinicalTrials.gov/show/NCT00309946
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
Recruitment: Recruiting
Conditions: Malignant Mesothelioma
Interventions: Drug: bortezomib|Drug: cisplatin
More Information: http://ClinicalTrials.gov/show/NCT00458913
Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II)
Recruitment: Recruiting
Conditions: Malignant Pleural Mesothelioma|MPM|Solid Tumors
Interventions: Drug: pemetrexed, cisplatin and CBP501|Drug: pemetrexed and cisplatin
More Information: http://ClinicalTrials.gov/show/NCT00700336
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
Recruitment: Recruiting
Conditions: Carcinoma, Non-Small-Cell Lung|Mesothelioma
Interventions: Drug: LBH 589
More Information: http://ClinicalTrials.gov/show/NCT00535951
Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
Recruitment: Recruiting
Conditions: Malignant Mesothelioma
Interventions: Drug: cisplatin|Drug: pemetrexed disodium|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: laboratory biomarker analysis|Procedure: neoadjuvant therapy|Procedure: quality-of-life assessment|Procedure: radiation therapy
URL: http://ClinicalTrials.gov/show/NCT00334594
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Recruitment: Recruiting
Conditions: Malignant Mesothelioma
Interventions: Drug: antineoplaston A10|Drug: antineoplaston AS2-1
URL: http://ClinicalTrials.gov/show/NCT00003508
Dendritic Cell-Based Immunotherapy in Mesothelioma
Recruitment: Recruiting
Conditions: Malignant Pleural Mesothelioma
Interventions: Biological: tumor lysate-loaded autologous dendritic cells
URL: http://ClinicalTrials.gov/show/NCT00280982
Study of Patients With Non-Small Cell Lung Cancer, Esophageal Cancer, or Malignant Pleural Mesothelioma
Recruitment: Recruiting
Conditions: Esophageal Cancer|Lung Cancer|Malignant Mesothelioma
Interventions: Procedure: DNA methylation analysis|Procedure: bronchoalveolar lavage|Procedure: bronchoscopy|Procedure: endoscopic biopsy|Procedure: gene expression analysis|Procedure: needle biopsy
URL: http://ClinicalTrials.gov/show/NCT00447447
Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery
Recruitment: Recruiting
Conditions: Malignant Mesothelioma
Interventions: Procedure: adjuvant therapy|Procedure: chemotherapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Procedure: radiation therapy
URL: http://ClinicalTrials.gov/show/NCT00253409
Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery
Recruitment: Recruiting
Conditions: Malignant Mesothelioma
Interventions: Drug: cisplatin|Drug: pemetrexed disodium|Drug: vitamin B12|Procedure: gene expression analysis|Procedure: laboratory biomarker analysis|Procedure: pharmacological study
URL: http://ClinicalTrials.gov/show/NCT00541073
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Recruitment: Recruiting
Conditions: Mesothelioma
Interventions: Drug: bevacizumab|Drug: cisplatin|Drug: pemetrexed
URL: http://ClinicalTrials.gov/show/NCT00295503
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Recruitment: Recruiting
Conditions: Mesothelioma
Interventions: Drug: Vinorelbine|Drug: Vandetanib
URL: http://ClinicalTrials.gov/show/NCT00597116
Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
Recruitment: Recruiting
Conditions: Malignant Pleural Mesothelioma
Interventions: Drug: Carboplatin and Vinorelbine
URL: http://ClinicalTrials.gov/show/NCT00272558
Vorinostat (MK0683, SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma
Recruitment: Recruiting
Conditions: Mesothelioma|Lung Cancer
Interventions: Drug: Suberoylanilide Hydroxamic Acid (SAHA)|Drug: Placebo (unspecified)
URL: http://ClinicalTrials.gov/show/NCT00128102
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma
Recruitment: Recruiting
Conditions: Mesothelioma
Interventions: Drug: NGR-hTNF
URL: http://ClinicalTrials.gov/show/NCT00484276
An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Recruitment: Recruiting
Conditions: Mesothelioma
Interventions: Drug: Milataxel
URL: http://ClinicalTrials.gov/show/NCT00685204
Extrapleural Pneumonectomy, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
Recruitment: Recruiting
Conditions: Malignant Pleural Mesothelioma
Interventions: Procedure: Extrapleural pneumonectomy (EPP)|Drug: cisplatin|Drug: gemcitabine|Drug: amifostine|Drug: sodium thiosulfate
URL: http://ClinicalTrials.gov/show/NCT00571298
Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
Recruitment: Recruiting
Conditions: Malignant Mesothelioma
Interventions: Drug: Valproate plus doxorubicin
URL: http://ClinicalTrials.gov/show/NCT00634205
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
Recruitment: Recruiting
Conditions: Leukemia|Lung Cancer|Malignant Mesothelioma|Myelodysplastic Syndromes|Peritoneal Cavity Cancer
Interventions: Drug: WT-1 analog peptide vaccine|Drug: incomplete Freund’s adjuvant|Drug: sargramostim|Procedure: flow cytometry|Procedure: immunoenzyme technique|Procedure: polymerase chain reaction
URL: http://ClinicalTrials.gov/show/NCT00398138
Decitabine and FR901228 in Treating Patients With Advanced Lung Cancer, Esophageal Cancer, Pleural Mesothelioma, or Lung Metastases
Recruitment: Recruiting
Conditions: Esophageal Cancer|Lung Cancer|Malignant Mesothelioma|Metastatic Cancer
Interventions: Drug: celecoxib|Drug: decitabine|Drug: romidepsin
URL: http://ClinicalTrials.gov/show/NCT00041158
Mesothelioma Avastin Plus Pemetrexed-Cisplatin Study
Recruitment: Recruiting
Conditions: Mesothelioma
Interventions: Drug: Standard Chemotherapy (Pemetrexed and Cisplatin)|Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
URL: http://ClinicalTrials.gov/show/NCT00651456
Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
Recruitment: Recruiting
Conditions: Non-Small Cell Lung Cancer|Mesothelioma|Lung Neoplasms
Interventions: Drug: pemetrexed
URL: http://ClinicalTrials.gov/show/NCT00316225
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Recruitment: Recruiting
Conditions: Soft Tissue Sarcoma|Mesothelioma
Interventions: Drug: Azacitidine In Combination With Temozolomide
URL: http://ClinicalTrials.gov/show/NCT00629343
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With MPM
Recruitment: Recruiting
Conditions: Mesothelioma
Interventions: Drug: Carboplatin, Bevacizumab and Pemetrexed
URL: http://ClinicalTrials.gov/show/NCT00604461
Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
Recruitment: Recruiting
Conditions: Malignant Epithelial Mesothelioma|Adenocarcinoma of the Pancreas|Carcinoma, Non-Small-Cell Lung|Adenocarcinoma of the Ovaries
Interventions: Biological: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
URL: http://ClinicalTrials.gov/show/NCT00585845
FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Esophageal, or Pleural Cancer
Recruitment: Recruiting
Conditions: Esophageal Cancer|Lung Cancer|Malignant Mesothelioma|Metastatic Cancer
Interventions: Drug: alvocidib|Drug: romidepsin
URL: http://ClinicalTrials.gov/show/NCT00098644
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
Recruitment: Recruiting
Conditions: Breast Cancer|Colorectal Cancer|Lung Cancer|Malignant Mesothelioma|Prostate Cancer|Psychosocial Effects/Treatment|Quality of Life|Thymoma and Thymic Carcinoma
Interventions: Procedure: educational intervention
URL: http://ClinicalTrials.gov/show/NCT00372840
Gene Therapy for Pleural Malignancies
Recruitment: Recruiting
Conditions: Pleural Mesothelioma|Metastatic Pleural Effusions
Interventions: Gene Transfer: BG00001 (adenoviral-mediated interferon-beta)
URL: http://ClinicalTrials.gov/show/NCT00299962
A Study To Find the Best Dose of SU011248 When Given With Pemetrexed, Pemetrexed and Cisplatin Or Pemetrexed and Carboplatin in Patients With Advanced Solid Tumors
Recruitment: Recruiting
Conditions: Non-Small Cell Lung Cancer|Mesothelioma|Neoplasms
Interventions: Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin
URL: http://ClinicalTrials.gov/show/NCT00528619
Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis
Recruitment: Recruiting
Conditions: Stomach Neoplasms|Colorectal Neoplasms|Neoplasm Metastasis|Mesothelioma
Interventions: Procedure: cytoreductive surgery|Procedure: intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin
URL: http://ClinicalTrials.gov/show/NCT00454519
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Recruitment: Recruiting
Conditions: Cancer
Interventions: Drug: fentanyl sublingual spray|Procedure: questionnaire administration
URL: http://ClinicalTrials.gov/show/NCT00538850
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Recruitment: Recruiting
Conditions: Solid Tumor|Lymphoma
Interventions: Drug: belinostat
URL: http://ClinicalTrials.gov/show/NCT00413075
Electronic Tool to Record Cancer Symptoms in Patients With Advanced Cancer Receiving Palliative Care
Recruitment: Recruiting
Conditions: Cancer
Interventions: Procedure: cognitive assessment|Procedure: counseling|Procedure: fatigue assessment and management|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment
URL: http://ClinicalTrials.gov/show/NCT00477919
Rapamycin With Grapefruit Juice for Advanced Malignancies
Recruitment: Recruiting
Conditions: Tumors|Neoplasm Metastasis
Interventions: Drug: Rapamycin (sirolimus)|Other: Grapefruit Juice
URL: http://ClinicalTrials.gov/show/NCT00375245
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Recruitment: Recruiting
Conditions: Advanced Solid Tumors
Interventions: Drug: OSI-930 and erlotinib
URL: http://ClinicalTrials.gov/show/NCT00603356
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Recruitment: Recruiting
Conditions: Ovarian Neoplasms|Colorectal Neoplasms|Melanoma|Small Cell Lung Cancer|Liposarcoma
Interventions: Radiation: Ionizing radiation (IR) therapy|Radiation: Ionizing radiation (IR)
URL: http://ClinicalTrials.gov/show/NCT00132704
Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer
Recruitment: Recruiting
Conditions: Cancer
Interventions: Drug: Pemetrexed|Drug: Bevacizumab
URL: http://ClinicalTrials.gov/show/NCT00222729
Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer
Recruitment: Recruiting
Conditions: Peritoneal Neoplasms|Retroperitoneal Neoplasms|Gastrointestinal Neoplasms|Adenocarcinoma|Neuroblastoma|Ovarian Neoplasms|Sarcoma|Adrenocortical Carcinoma|Wilms Tumor|Rhabdomyosarcoma|Desmoplastic Small Round Cell Tumor
Interventions: Drug: Cisplatin
URL: http://ClinicalTrials.gov/show/NCT00436657
Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer
Recruitment: Recruiting
Conditions: Cancer of the Head and Neck
Interventions: Drug: Gemcitabine|Drug: Oxaliplatin
URL: http://ClinicalTrials.gov/show/NCT00256295